发明名称 |
SPLICE SWITCHING OLIGOMERS FOR TNF SUPERFAMILY RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE |
摘要 |
The present invention relates to splice switching oligonucleotides or splice switching oligomers (SSOs). The preferred SSOs according to the invention target exon 7 of TNFR1 (TNFRSF1A) or TNFR2 (TNFRSF1A) pre-mRNA, typically resulting in the production of TNFR variants which comprise a deletion in part or the entire exon 7 respectfully. SSOs targeting exon 7 are found to result in a soluble form of the TNFR, which has therapeutic benefit for treatment of inflammatory diseases. The SSO's are characterized in that they are substantially incapable or incapable of recruiting RNaseH. |
申请公布号 |
AU2016203220(A1) |
申请公布日期 |
2016.06.09 |
申请号 |
AU20160203220 |
申请日期 |
2016.05.17 |
申请人 |
ERCOLE BIOTECH, INC.;SANTARIS PHARMA A/S |
发明人 |
ØRUM, HENRIK;SAZANI, PETER L. |
分类号 |
A61K31/713;C12N15/11;A61K48/00;C07H21/00;C12N15/113 |
主分类号 |
A61K31/713 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|